L.Grozdinski and I.Petrov, M.Iloska,M.Pavlova

Slides:



Advertisements
Similar presentations
Inflammation and Neurodegeneration in Multiple Sclerosis
Advertisements

MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
An Introduction to Multiple Sclerosis. What is MS? Common symptoms. Diagnosis & potential treatments. Case Studies Support for people with MS and carers.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Degenerative Myelopathy Copyright University of Florida 1998 Of German Shepherd Dogs A chronic, progressive neurodegenerative disease Initial signs are.
Multiple Sclerosis Definition: Multiple sclerosis (MS) is a disease of the central nervous system (CNS); it damages the protective coating around the.
MS as a Vascular Disease: Background and History
Rituximab (RITUXAN) & Multiple Sclerosis
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
FREEDOMS II TRIAL.
Short-term outcomes after endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis Kenneth Mandato,
1 Trevor W Tucker, PhD Fluid Dynamics: The MS – CCSVI Missing Link? Presented At The NCS Conference “Les voix du progrès :: Voices of Progress” Sherbooke,
Multiple Sclerosis (MS) By: Morgan Farr Biology 1010.
Multiple Sclerosis Jessica Kelly-Hannon It’s causes, effects and treatments.
Friends With MS.com Bringing you support and information for Multiple Sclerosis.
What is Multiple Sclerosis (MS)? an unpredictable disease of the central nervous system, which can range from relatively benign to somewhat disabling.
Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.
Endovascular management of CCSVI: Single Center Experience Hector Ferral, MD, George Behrens, MD, Yanki Tumer, MD, Tameem Souman, MD.
Multiple Sclerosis (MS) Henry Wilson March 6, 2013 Honors Psychology 4th.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative.
Multiple Sclerosis Alan Chen 4/1/14. General Information Other names: disseminated sclerosis or encephalomyelitis disseminata Inflammatory disease that.
© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.
Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.
Multiple Sclerosis Jesse Mohoric and Sarah Davis.
STUDY OF THE CHRONIC CEREBRO-SPINAL VENOUS INSUFFICIENCY IN A POPULATION OF YOUNG PEOPLE WITH MULTIPLE SCLEROSIS BY HEMODYNAMIC MAP MORPHOLOGICAL S. MANDOLESI;
MULTIPLE SCLEROSIS Ana Costas Barreiro.
Mind, Brain & Behavior Wednesday January 29, 2003.
Nervous System Unit 6.8 Pages
Adult Medical-Surgical Nursing Neurology Module: Neurological Dysfunction.
Dennis Bourdette, MD VA MS Center of Excellence-West and
What is Multiple Sclerosis (MS)? Autoimmune disease Affects 2.3 million people in the world 3 Types Relapsing-remmitting Primary-progressive Secondary-progressive.
Multiple Sclerosis By Birger Flønæs & Christoffer Brovold.
MULTIPLE SCLEROSIS BY EMILY HOWARD. Multiple Sclerosis (MS) Multiple sclerosis (or MS) is a chronic, often disabling disease of the immune system that.
Multiple Sclerosis And Controversies Around it University of Puerto Rico in Humacao.
Multiple Sclerosis & H1N1 Flu Virus Crosson Nipper, Lauren Kline, Lee Boone.
Zookeeper genetic disorder By nick proffitt. Multiple sclerosis Multiple sclerosis also known as MS is a long lasting disease that can affect the brain.
Long Term Lyme 3 stages of Lyme Disease. Stage 1: Early Localized (previous slides) Stage 2: Early Disseminated – Weeks to Months – Affects skin, joints,
Multiple Sclerosis (MS) a serious, chronic and debilitating disease What is MS? A disease of the brain and spinal cord.
Multiple Sclerosis. What is MS? This is a chronic and often disabling disease in which the body’s immune system (t-cells) attacks the central nervous.
Multiple Sclerosis. Multiple sclerosis (MS) is a disease that affects central nervous system (brain and spinal cord). It damages the myelin sheath. 
POLISH EXPERIENCE IN CCSVI TREATMENT Marian Simka EuroMedic Department of Vascular & Endovascular Surgery Katowice Poland.
CATEGORY: IMMUNE DYSFUNCTION Multiple Sclerosis Lindsay Nicholson, University of Bristol, UK [ Multiple sclerosis (MS) is.
In The Name of God. Multiple Sclerosis and Normal MRI new modalities for problems solving.
Cerebral Sinus Venous Thrombosis
Endovascular treatment of CCSVI really works: the benefits of treating venous brain congestion can be documented Ivo Petrov, MD, PhD Sofia City Clinic.
Four Known Types of MS Clinically isolated syndrome (CIS)
Clinical Immunology Jasmina Makarevic
Multiple Sclerosis GP Role
CCSVI: can we justify the procedure at this time?
Multiple Sclerosis [
Claire Bischoff, Ashley folden, and Cassie Newman
CCSVI Richard F. Neville, MD Professor of Surgery
Epidemiology of CCSVI in MS using ECD-TCCS and venography
Michael R. Jaff, DO Conflicts of Interest
Marian Simka, MD PhD Katowice, Poland
PTCA treatment for MS: Techniques and Outcomes
CORRELATION OF BIOMARKERS FOR AXONAL DEGENERATION WITH RETINAL NERVE FIBER LAYER THICKNESS AND DISABILITY IN DIFFERENT PHASES OF MULTIPLE SCLEROSIS UZUNKOPRU.
By: Julie Carrasco, Brianna Macias, Alexx Rusake
CCSVI: Can We Justify this Procedure at this Time? - Pro -
A light in a dark room for people with (MS), (CP) and Leukodystrophy
Characteristic time courses for various neurologic disorders
Guillain-Barre Syndrome (Polyneuritis)
Stephen L. Hauser, Jorge R. Oksenberg  Neuron 
A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency  Paolo Zamboni, MD, Roberto Galeotti, MD, Erica.
Volume 20, Issue 1, Pages (February 2013)
Created by Educational Technology Network
Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis  Tommaso Lupattelli,
Figure 7 VEGF as a mediator of neuroinflammatory disease
Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.
Disease of the Central Nervous System By Eric Nauman
Presentation transcript:

Relationship between chronic cerebro-spinal venous insufficiency CCSVI and MS L.Grozdinski and I.Petrov, M.Iloska,M.Pavlova Clinic of Angiology and Phlebology Tokuda Hospital Sofia, Bulgaria

Multiple sclerosis (MS) This is an inflammatory, neurodegenerative, disease of the central neurological system (brain, spine); It was first discovered by Charcot, 1868

Frequency and occurance Two million people suffer from MS in the world Highest frequency have North America and North Europe up to 80/100 000

Specifics and prognosis MS affects young people between 25 – 35 years; Patients with MS live 5-10 years less than the rest of the people; After 25 years over 50% of the patients become dissabled.

Axon – myelin affection Autoimmune theory for development of MS Infection causing BBB breakdown, myelin affection - autoimmune reaction and MS Genetic factors Infections BBB Breakdown Virus Attack Causing Axon – myelin affection T-kyller lymphocytes Autoimmune reaction Demyelination Neuron MS Lymphocytes

Unsolved questions The ethiological and pathogenetic mechanism stil stay uncleared; There′s no explanation why the BBB is breaking down; There′s no explanation why the inflamatory reaction is around the cerebral vein;

2009 P.Zamboni discovers CCSVI in patients with MS CCSVI is congenital venous malformation – stenoses of internal jugular and azygous veins and insufficient cerebrospinal venous drainage.

Zambony`s theory of CCSVI- MS Disturbed venous drainage Venous hypertention Disturbed of BBB Migration of blood cells Er – precipitation of iron Irons causes neurodegeneration CCSVI causes:

US – Color Doppler Study of Jugular vein Total tesded – 550 patients Control group – 50 p without MS; Group A – 500 p with MS Results: Control group – 46 p without date for CCSVI and 4 p (8%) suspected for CCSVI Group A (MS) – 461 p – 92,2% comfermed for CCSVI and 39 p – 7,8% without proven date for CCSVI

Bozev (MS)– Stenosis of Jugular vein – US screening

Zarev(MS) – Stenosis of IJV – US screening

K.G.( MS ). Valve stenosis of RIJV US - screening I.P

A.R.(MS) Valve stenosis and insuff. of IJV US screening

Study with venography Exzamined - 461 p with CCSVI – MS found with US Patients were from: Bulgaria, Canada, UK, Irland,USA, Holand, Italy, France, Slovenia, Hungary, Greece, Suisse, Norwey,Litva, Macedonia, Croatia,Malta,Rumenia,Kipar,Harvatia

Forms of MS and clinical stage Relapsing Remitting – 278 p – 55.6% Primary progressive – 177 p – 35,4% Secondary progressive – 38 p – 7,6% Clinicaly isolated syndrom – 7 p – 1,4 % EDSS – average – 5.2 stage Continuance of MS – 9 years

Color Doppler screening of IJV Total 550 p. Control gr.О–50p. mean,SD, n , % Gr.A– MS 500 p. Gr.А1-461 p. CCSVI Gr.А2- 39 p. Мах.D IJV в мм. 8.2 +-2.8 8.6 +-3.2 8.7 +-3.1 8.5 +- 2.9 Min.D IJV в мм. 4.5+-1.7 1.8+-3.7* 1.7+-3.5* 3.1 +- 3.2* min.d/max.d% 54% 20%* 19%* 36% Stenosis in ІJV 5% 92%* 100%* 5 % Reflux in IJV 7% 67 %* 70 %* 12 % Reduction of flow in IJV 6 % 50 %* 73%* 12% -ΔCSA в IJV 2% 63%* 66%* 0 % 8 % 92 %* CCSVI 4 10 % 123 89.1%* 123 100%* 0 0 %

Venography In 461 patients with CCSVI –MS found by US , venography confirmed CCSVI in 100%; Jugular vein stenoses – 461 p. – 100% Jugular vein + Azygos stenoses – 339 p – 73,5% Independetly jugular vein stenoses – 122 p, 26,4% Stenoses were over 60% to 99%.

Venography - IJV -МS

Comparison - Color Doppler and venography CCSVI - MS CCSVI 461 p. 1383 vein ColorDoppler total 922 IJV Venography 1383 n.,% Vein stenosis – n vein 793 86 % 1112 80.4% Vein stenosis - patient 461 100% Stenosis IJV – vein 86% 773 83.8% Stenosis IJV – p. Stenosis v.azygos - 339 73.5%

CCSVI -US Doppler diagnostic/Venography comparison CCSVI diagnostic US sensitivity – 98%; Concurrence – 91,6%

Stenosis IJV before and after endovascular treatment

Stenosis vena azygos – before and after endovascular treatment

Clinical improvement after endovascular treatment Early improvement up to one week – 81%; Improvment up to 6 months – 60%

Venous theory of MS VT CCSVI - CVI Valve stenosis/ Stenosis insufficiency Stenosis v. Jugularis/ Azygos Reflux VBP venous drainage Er (Fe) fibrin ED Destruction of BBB Insufficiency T-Lymp infiltration perivascular edema disturbed microcirculation CO2 O2 progressive neurodegenerative disease autoimmune process Neurodegenerative disease - MS

Conclusion In patients suffering from MS a high frequency of CCSVI is established (using US and Venography) This proves relationship between MS and CCSVI. MS simptoms improve after the endovascular treatment